Business Context and Reporting Period
This Form 8-K is filed by Leap Therapeutics, Inc. (noting a discrepancy with the metadata name "Cypherpunk Technologies Inc.") on September 10, 2025. The report addresses Item 3.01 regarding the notice of delisting or failure to satisfy a continued listing rule on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on stock listing compliance status rather than financial performance metrics.
Material Changes and Listing Status
- Initial Deficiency: On March 12, 2025, the Company received notice that its closing bid price had been below the required $1.00 per share for 30 consecutive business days.
- First Compliance Period: The Company had until September 8, 2025, to regain compliance but failed to maintain the $1.00 bid price.
- Second Compliance Period Granted: On September 10, 2025, Nasdaq granted an additional 180 calendar days (until March 9, 2026) to cure the bid price deficiency.
- Conditions Met: The extension was granted because the Company met all other initial listing requirements, including the market value of publicly held shares.
Outlook, Management Commentary, and Risks
Management intends to monitor the closing bid price and may implement a reverse stock split to regain compliance. However, the filing explicitly states there is no assurance that the Company will be able to regain compliance or maintain other listing requirements during the extension period. If compliance is not demonstrated by March 9, 2026, the Company faces delisting. The Company may appeal a delisting determination, but success is not guaranteed.
Investor Verification Checklist
- Verify the current closing bid price of LPTX common stock relative to the $1.00 threshold.
- Confirm whether the Company has filed a formal plan for a reverse stock split with Nasdaq.
- Monitor for any additional Nasdaq notifications regarding compliance with other listing standards (e.g., market value of publicly held shares) during the grace period.
- Review the Company's most recent financial filings to assess liquidity and capital resources available to support operations if delisting occurs.